StockNews.AI
BBNX
StockNews.AI
61 days

Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott's Future Dual Glucose-Ketone Sensor

1. Beta Bionics to integrate iLet with Abbott's dual glucose-ketone sensor. 2. iLet is the first AID system making fully automated insulin decisions. 3. Integration aims to enhance real-time decision-making for diabetes management. 4. Collaboration with Abbott reinforces commitment to advanced diabetes solutions. 5. iLet is designed to significantly improve health outcomes for insulin users.

4m saved
Insight
Article

FAQ

Why Bullish?

The advancements in diabetes tech could lead to increased market demand and BBNX’s valuation. Historical pre-launch spikes in similar tech firms suggest positive investor response.

How important is it?

The announcement signifies critical innovation within the diabetes management sector, enhancing iterative growth potential for BBNX.

Why Long Term?

Integration and development in healthcare tech often yield lasting impacts; akin to Dexcom’s long-term growth following its advancements.

Related Companies

ABTDXCMTNDM
June 19, 2025 07:00 ET  | Source: Beta Bionics, Inc. IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's future dual glucose-ketone sensor in the U.S. The iLet represents a significant advancement in diabetes care as the first and only AID system that makes 100% of insulin dosing decisions automatically. With the iLet, people living with diabetes can achieve excellent clinical outcomes without the burden of carb counting* or manual insulin correction calculations. The system currently supports Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring sensor, and this future design further extends the collaboration between Beta Bionics and Abbott, reinforcing their shared commitment to bringing cutting-edge diabetes solutions to the market. “This integration holds great promise for further enhancing real-time decision-making support for people living with diabetes,” said Sean Saint, President and CEO of Beta Bionics. “As the benchmark in automated insulin delivery systems, the iLet will naturally integrate with Abbott's future dual glucose-ketone sensor as soon as it becomes commercially available.” *User must be carb aware About Beta BionicsBeta Bionics is a commercial-stage medical technology company dedicated to simplifying diabetes management and improving outcomes for people requiring insulin therapy. By leveraging advanced adaptive algorithms, Beta Bionics has developed the iLet® Bionic Pancreas—the first FDA-cleared insulin delivery device with a fully autonomous insulin dosing algorithm. Designed to significantly enhance health outcomes and quality of life across a broad spectrum of individuals with diabetes, the iLet sets a new standard in diabetes care. For more information, visit www.betabionics.com. Important Safety Information Product for prescription only. For important safety information, please visit https://www.freestyle.abbott/us-en/safety-information.html. Investor Relations Contact:ir@betabionics.com Media and Public Relations Contact:media@betabionics.com

Related News